Biosimilar monoclonal antibodies in China: A patent review.

ABSTRACT: Biosimilars play an important role in reducing the burden on patients and increasing the market competition. Biosimilar monoclonal antibodies are currently one of the hotspots of research and development in China with policies support. With the continuous improvement of policies, the enthusiasm for the research and development of biosimilars has increased year by year. The policy requirements in different periods have different degrees of impact on the patent applications of pharmaceutical companies. This review introduces the biosimilar monoclonal antibodies market status and approval process in China, analyzes the patents in this field, and helps pharmaceutical companies protect their intellectual property rights.

SUBMITTER: Liu JW 

PROVIDER: S-EPMC9342192 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature